EMERGENT BIOSOLUTIONS INC. Effective Income Tax Rate Reconciliation, Nondeductible Expense, Percent
EMERGENT BIOSOLUTIONS INC. (EBS) reported Effective Income Tax Rate Reconciliation, Nondeductible Expense, Percent of 25.00% for the 9-month period ending 2020-09-30, per its 10-Q filed 2020-11-06.
Discontinued › Expense Statement › Income Tax
us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense · last filed 2020-11-06
- 2020-09-30: Effective Income Tax Rate Reconciliation, Nondeductible Expense, Percent 9 month 25.00%.
- 2019-09-30: Effective Income Tax Rate Reconciliation, Nondeductible Expense, Percent 9 month 24.00%.
| Period end | Effective Income Tax Rate Reconciliation, Nondeductible Expense, Percent 9 month |
|---|---|
| 2020-09-30 | 25.00% 10-Q · filed 2020-11-06 |
| 2019-09-30 | 24.00% 10-Q · filed 2020-11-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ENANTA PHARMACEUTICALS INC (ENTA) | United States | $0.349B | -6.72 |
| Larimar Therapeutics, Inc. (LRMR) | United States | $0.344B | -1.83 |
| Vogenx, Inc. (VOGX) | United States | $0.355B | |
| Benitec Biopharma Inc. (BNTC) | United States | $0.337B | -10.08 |
| BioAge Labs, Inc. (BIOA) | United States | $0.333B | -11.88 |
| BridgeBio Oncology Therapeutics, Inc. (BBOT) | United States | $0.320B | -3.35 |
| Evommune, Inc. (EVMN) | United States | $0.320B | -5.10 |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| Rezolute, Inc. (RZLT) | United States | $0.382B | -6.45 |